Results 151 to 160 of about 32,676 (224)

Residue‑resolved dynamically averaged interaction analysis of direct factor Xa inhibitors by MD‑FMO combination calculations. [PDF]

J Comput Aided Mol Des
Yoshine R, Hirano Y, Doi H, Kitahara S, Akisawa K, Okuwaki K, Yamamoto E, Yasuoka K, Mochizuki Y.   +8 more
europepmc   +1 more source

Comparison of aspirin and rivaroxaban for the prevention of pulmonary embolism and deep vein thrombosis in high thrombotic risk patients with systemic lupus erythematosus: study protocol for a multicentre, prospective, randomised controlled trial. [PDF]

Lupus Sci Med
Zhang Z, Li F, Li Y, Xie Z, Du J, Mao N, Li S, Liu Y, Ge Y, Wang J, Tang Q, Kang J, Peng X, Cheng W, Li Y, Xu P, Xiao Y, Tu T, Xie X, Liu Q.   +19 more
europepmc   +1 more source

Real-world use of rivaroxaban for primary thromboprophylaxis and cardiac thrombosis treatment in congenital and acquired heart disease: a prospective cohort study. [PDF]

Sci Rep
Derridj N, Malekzadeh-Milani S, Lasne D, Da Costa S, Khraiche D, Ndjoli H, Bonnet D, Bajolle F.   +7 more
europepmc   +1 more source

Trousseau syndrome presenting with recurrent multi-territory infarctions: a case report of two patients highlighting divergent outcomes and dynamic hypercoagulability under direct oral anticoagulants and low-molecular-weight heparin. [PDF]

Front Cardiovasc Med
Ding G, Xu J, Yao M.
europepmc   +1 more source

Enhancement of the Solubility and Dissolution Profile of Rivaroxaban by the Antisolvent Precipitation Technique: A Promising Approach. [PDF]

Polymers (Basel)
Benga CM, Ozon EA, Musuc AM, Anuța V, Sârbu I, Surdu VA, Teodorescu F, Rusu A, Popa L, Ghica MV, Chandak A, Pîrvu CED.   +11 more
europepmc   +1 more source

Pharmaceutical Co-Crystal Formulation of Rivaroxaban with Niacinamide: Preparation, Characterization, and In Vitro Release Evaluation. [PDF]

Materials (Basel)
Solomon C, Sarbu I, Anuța V, Ozon EA, Musuc AM, Rusu A, Surdu VA, Chandak A, Gavriloaia RM, Fița AC, Nită DT, Mitu MA.   +11 more
europepmc   +1 more source

The influence of ABCB1 rs4148738 (C>T) polymorphism on rivaroxaban exposure and bleeding risk in Iraqi patients with non-valvular atrial fibrillation. [PDF]

Qatar Med J
Jalel HK, Hamid MO, Ibadi MH.
europepmc   +1 more source

Direct oral anticoagulants versus warfarin for left ventricular thrombus: an updated systematic review and meta-analysis of randomized and observational studies. [PDF]

Front Cardiovasc Med
Alfehaid L, Alhuwayshil J, Almousa S, Habeeb E, Al Yami MS.   +4 more
europepmc   +1 more source

Methodological Concerns Regarding a Recent Meta-Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation. [PDF]

Clin Cardiol
Samir OK, Datta N.
europepmc   +1 more source

Safety and effectiveness of rivaroxaban thromboprophylaxis in adrenocorticotropic hormone-dependent Cushing syndrome.

J Clin Endocrinol Metab
Htut Z, Mundhra A, Lazarus K, Martin N, Papadopoulou D, Meeran K, Wernig F.   +6 more
europepmc   +1 more source